vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and TPG Mortgage Investment Trust, Inc. (MITT). Click either name above to swap in a different company.
TPG Mortgage Investment Trust, Inc. is the larger business by last-quarter revenue ($20.4M vs $15.0M, roughly 1.4× CHAMPIONS ONCOLOGY, INC.). TPG Mortgage Investment Trust, Inc. runs the higher net margin — 65.0% vs 1.8%, a 63.2% gap on every dollar of revenue. On growth, TPG Mortgage Investment Trust, Inc. posted the faster year-over-year revenue change (17.7% vs 11.5%). Over the past eight quarters, CHAMPIONS ONCOLOGY, INC.'s revenue compounded faster (11.8% CAGR vs 9.1%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
TPG Mortgage Investment Trust, Inc. is a real estate investment trust managed by global alternative asset firm TPG. It primarily invests in residential and commercial mortgage-backed securities, performing and non-performing mortgage loans, and other credit-linked real estate assets, with its core market being the United States. It generates returns via net interest income from holdings and strategic asset disposition gains.
CSBR vs MITT — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $20.4M |
| Net Profit | $268.0K | $13.3M |
| Gross Margin | 51.7% | — |
| Operating Margin | 1.2% | 67.1% |
| Net Margin | 1.8% | 65.0% |
| Revenue YoY | 11.5% | 17.7% |
| Net Profit YoY | -63.2% | -7.0% |
| EPS (diluted) | $0.02 | $0.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $20.4M | ||
| Q3 25 | $14.0M | $19.5M | ||
| Q2 25 | $12.4M | $17.8M | ||
| Q1 25 | $17.0M | $18.8M | ||
| Q4 24 | $13.5M | $17.4M | ||
| Q3 24 | $14.1M | $14.9M | ||
| Q2 24 | $14.0M | $16.4M | ||
| Q1 24 | $12.0M | $17.2M |
| Q4 25 | $268.0K | $13.3M | ||
| Q3 25 | $-436.0K | $20.0M | ||
| Q2 25 | $-1.8M | $3.9M | ||
| Q1 25 | $4.5M | $11.5M | ||
| Q4 24 | $728.0K | $14.3M | ||
| Q3 24 | $1.3M | $16.6M | ||
| Q2 24 | $-109.0K | $3.9M | ||
| Q1 24 | $-2.5M | $20.9M |
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 1.2% | 67.1% | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | -16.2% | 20.9% | ||
| Q1 25 | 26.4% | 54.6% | ||
| Q4 24 | 5.4% | 76.7% | ||
| Q3 24 | 9.5% | — | ||
| Q2 24 | -1.9% | 18.4% | ||
| Q1 24 | -21.4% | — |
| Q4 25 | 1.8% | 65.0% | ||
| Q3 25 | -3.1% | 102.5% | ||
| Q2 25 | -14.9% | 22.2% | ||
| Q1 25 | 26.4% | 60.9% | ||
| Q4 24 | 5.4% | 82.2% | ||
| Q3 24 | 9.3% | 111.3% | ||
| Q2 24 | -0.8% | 24.0% | ||
| Q1 24 | -21.1% | 121.6% |
| Q4 25 | $0.02 | $0.27 | ||
| Q3 25 | $-0.03 | $0.47 | ||
| Q2 25 | $-0.12 | $-0.05 | ||
| Q1 25 | $0.31 | $0.21 | ||
| Q4 24 | $0.05 | $0.30 | ||
| Q3 24 | $0.09 | $0.40 | ||
| Q2 24 | $-0.01 | $-0.02 | ||
| Q1 24 | $-0.19 | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $57.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $560.7M |
| Total Assets | $30.2M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $57.8M | ||
| Q3 25 | $10.3M | $59.0M | ||
| Q2 25 | $9.8M | $88.7M | ||
| Q1 25 | $3.2M | $115.5M | ||
| Q4 24 | $2.8M | $118.7M | ||
| Q3 24 | $2.9M | $102.5M | ||
| Q2 24 | $2.6M | $120.9M | ||
| Q1 24 | $4.5M | $100.3M |
| Q4 25 | $4.2M | $560.7M | ||
| Q3 25 | $3.5M | $559.8M | ||
| Q2 25 | $3.8M | $536.4M | ||
| Q1 25 | $5.5M | $543.9M | ||
| Q4 24 | $681.0K | $543.4M | ||
| Q3 24 | $-332.0K | $540.1M | ||
| Q2 24 | $-1.9M | $533.5M | ||
| Q1 24 | $-2.1M | $539.6M |
| Q4 25 | $30.2M | $8.7B | ||
| Q3 25 | $30.5M | $9.0B | ||
| Q2 25 | $32.3M | $7.5B | ||
| Q1 25 | $30.6M | $7.3B | ||
| Q4 24 | $25.2M | $6.9B | ||
| Q3 24 | $24.9M | $7.0B | ||
| Q2 24 | $26.1M | $7.1B | ||
| Q1 24 | $26.8M | $6.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $59.6M |
| Free Cash FlowOCF − Capex | $-2.0M | — |
| FCF MarginFCF / Revenue | -13.1% | — |
| Capex IntensityCapex / Revenue | 1.6% | — |
| Cash ConversionOCF / Net Profit | -6.47× | 4.48× |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $59.6M | ||
| Q3 25 | $600.0K | $17.4M | ||
| Q2 25 | $6.9M | $11.5M | ||
| Q1 25 | $490.0K | $12.0M | ||
| Q4 24 | $-283.0K | $55.8M | ||
| Q3 24 | $311.0K | $14.5M | ||
| Q2 24 | $-1.8M | $13.7M | ||
| Q1 24 | $-919.0K | $12.0M |
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | -6.47× | 4.48× | ||
| Q3 25 | — | 0.87× | ||
| Q2 25 | — | 2.92× | ||
| Q1 25 | 0.11× | 1.05× | ||
| Q4 24 | -0.39× | 3.91× | ||
| Q3 24 | 0.24× | 0.87× | ||
| Q2 24 | — | 3.50× | ||
| Q1 24 | — | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
MITT
Segment breakdown not available.
